FDA Expands Opioid Abuse Research, Outreach
Executive Summary
US agency signs contracts for more real-world data on abuse; officials also meet with AMA representatives to discuss opioid prescriber education.
You may also be interested in...
US FDA Says Opioid Database Firm With Purdue Pharma Connections Reported No Conflicts
Amid criticism of its contract to evaluate opioid data from the Researched Abuse, Diversion and Addiction-Related Surveillance (RADARS) survey programs, the FDA says federal databases lack the necessary information on opioid misuse.
FDA Contract Awards In Brief: Regenerative Medicine, eCTD, Reg Science
Contracts US agency awarded as fiscal year 2017 came to a close include one to Nexight for a regenerative medicine standards development process, another to Lorenz to manage eCTD submissions – and 26 more for regulatory science R&D.
Opioid Hearing: Senators Want Speed, But Agency Heads Stress Time, Effort
Reeducating prescribers on treating pain will take a long time, FDA Commissioner Scott Gottlieb tells Senate HELP Committee Members.